- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 29.03. | AN2 Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 29.03. | AN2 Therapeutics, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 29.03. | AN2 Therapeutics GAAP EPS of -$0.57 beats by $0.17 | 1 | Seeking Alpha | ||
| 28.03. | AN2 Therapeutics reports FY results | 1 | Seeking Alpha | ||
| 28.03. | AN2 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business and Scientific Highlights | 176 | Business Wire | MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious... ► Artikel lesen | |
| 13.02. | Leerink cuts AN2 Therapeutics stock target to $7 from $23 | 4 | Investing.com | ||
| 13.02. | US An2 Therapeutics, Par Technology, Trimble | 5 | Reuters | ||
| 12.02. | Oppenheimer cuts AN2 Therapeutics to Perform on trial pause | 4 | Investing.com | ||
| 12.02. | AN2 Therapeutics to pause enrollment in lung disease study, shares plummet | 3 | Reuters | ||
| 12.02. | Why Is Infectious Disease-Focused AN2 Therapeutics Stock Sinking Today? | 2 | Benzinga.com | ||
| 12.02. | AN2's stock craters as phase 3 lung disease trial for lead antibiotic paused over efficacy | 4 | FierceBiotech | ||
| 12.02. | Monday.com Reports Q4 Results, Joins AN2 TherapeuticsAnd Other Big Stocks Moving Lower In Monday's Pre-Market Session | 9 | Benzinga.com | ||
| 12.02. | AN2 Therapeutics plunges after pause on pivotal trial | 1 | Seeking Alpha | ||
| 12.02. | AN2 Therapeutics plummets as co to pause enrollment in lung disease study | 3 | Reuters | ||
| 12.02. | AN2 Therapeutics Stock Plummets On Decision To Pause Enrollment In Epetraborole Phase 2/3 Trial | 2 | RTTNews | ||
| 12.02. | AN2 Therapeutics halts phase 3 trial enrollment for drug study | 1 | Investing.com | ||
| 12.02. | AN2 Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 10.11.23 | AN2 Therapeutics reports Q3 results | 1 | Seeking Alpha | ||
| 09.11.23 | AN2 Therapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 09.11.23 | AN2 Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings |
Seite:
1 2 Weiter >>
23 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EPIGENOMICS | 1,545 | -5,21 % | EQS-NVR: Epigenomics AG: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 41 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Gesamtstimmrechtsmitteilung: Epigenomics AG
/ Veröffentlichung der Gesamtzahl der Stimmrechte
Epigenomics AG: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 41 WpHG... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,860 | +1,18 % | Kaufen nach Abverkauf? Defence Therapeutics, Infineon Technologies, Super Micro Computer, TSMC Aktie | Die Marktteilnehmer waren nach den starken Kursrückgängen von Dow Jones und DAX sehr nervös. Schon panikartig wurden in der Nacht zu Freitag viele Aktien und damit auch Indizes abverkauft. Erst in den... ► Artikel lesen | |
| GINKGO BIOWORKS | 0,860 | +10,30 % | Looking Into Ginkgo Bioworks Holdings' Recent Short Interest | ||
| BEAM THERAPEUTICS | 21,360 | -1,11 % | Expert Ratings For Beam Therapeutics | ||
| ONCOLYTICS BIOTECH | 1,010 | -1,94 % | Oncolytics Biotech® Inc.: Oncolytics Biotech® Announces Upcoming Presentations at the American Society of Clinical Oncology Annual Meeting | SAN DIEGO and CALGARY, AB, April 25, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology,... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 8,120 | +3,57 % | Best biotech stocks to buy and hold in 2024: VKTX, SANA, RXRX | ||
| ARCTURUS THERAPEUTICS | 26,550 | +1,45 % | Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress | SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease... ► Artikel lesen | |
| ASSERTIO | 0,828 | +5,49 % | Assertio Holdings, Inc. to Report First Quarter 2024 Financial Results on May 6, 2024 | ||
| SIGA TECHNOLOGIES | 8,790 | +1,74 % | SIGA Technologies - Positive signals abound | SIGA Technologies announced a strategic step in fortifying its distribution partner, Meridian, allowing greater control over planning and executing its international development efforts, a key growth... ► Artikel lesen | |
| MERRIMACK PHARMACEUTICALS | 14,730 | 0,00 % | Merrimack Pharmaceuticals, Inc. Reports Full Year 2023 Financial Results | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) ("Merrimack" or the "Company") today announced its full year 2023 financial results for the period ended December... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 8,230 | +7,86 % | How Vir found the one: CEO Marianne De Backer | ||
| VERVE THERAPEUTICS | 6,140 | -1,29 % | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BOSTON, March 28, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing... ► Artikel lesen | |
| ARS PHARMACEUTICALS | 8,350 | +3,21 % | ARS Pharmaceuticals, Inc.: ARS Pharmaceuticals Submits Response to FDA Complete Response Letter for neffy (Epinephrine Nasal Spray) | Response addresses all additional requests in FDA CRL, including positive data from a repeat dose PK/PD study of neffy under nasal allergen challenge (NAC) conditions, and updated testing that detected... ► Artikel lesen | |
| BIO-PATH | 2,680 | +1,71 % | Bio-Path files to sell 484K shares of common stock for holders | ||
| BIOMEA FUSION | 10,780 | +2,96 % | Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | REDWOOD CITY, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA) ("Biomea" or the "Company"), a clinical stage biopharmaceutical company focused on the discovery and development... ► Artikel lesen |
Das Unternehmen AN2 THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +1,97 % bei einem Aktienkurs von 2,325 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
